Search Results

You are looking at 241 - 250 of 2,860 items for :

  • Refine by Access: All x
Clear All
Full access

HSR22-180: Real-World Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy in BRAF+ Cutaneous Melanoma Patients Treated in the Adjuvant Setting

Sanjay Chandrasekaran, You-Li Ling, Jackson Tang, Deborah Norton, and Rohan Shah

use in the real-world setting is scarce. Objective : To examine treatment patterns and outcomes among BRAF+ cutaneous melanoma patients treated with adjuvant IO or DT in the United States. Methods: This was a retrospective cohort study using

Full access

CLO22-068: An Assessment of Extended Pembrolizumab Dosing and Outcomes in Advanced Non-Small Cell Lung Cancer Patients During the COVID-19 Pandemic

Gordon Taylor Moffat, Lilian Hanna, Wilma Hopman, Andrea S. Fung, and Pierre-Olivier Gaudreau

to the cancer center. Pembrolizumab ED has been evaluated through pharmacokinetic studies and simulated model-based analyses, however clinical data are lacking. The aim of this study is to evaluate real-world outcomes and safety of ED vs standard

Full access

HSR21-050: Access to Gastroenterology and Internal Medicine Physicians is Associated With Improved Outcomes in Colorectal Cancer: A Nation-Wide Analysis

Udhayvir Singh Grewal, Subhash Chandra Garikipati, Parth Rajeshbhai Shah, Shiva Jashwanth Gaddam, Aakash Rajendra Sheth, and Ghanshyam Mudigonda

conducted the current analysis to study the impact of access to various specialties on the overall outcomes in CRC patients. Materials and Methods: The National Provider Identifier (NPI) database was interrogated to identify the number of gastroenterology

Full access

HSR23-101: Characteristics and Outcomes of Patients Treated With Selpercatinib in the Real-World: A Retrospective Study Using US Claims Databases

Naleen Raj Bhandari, Neha Bansal, Chi-Wei Duann, Anasofia Afonso, and Shen Zheng

and associated outcomes (time to treatment discontinuation [TTD] and treatment adherence) in selpercatinib-treated US patients. Methods: This retrospective cohort study used de-identified data from two administrative real-world claims databases

Full access

Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing Period

Aida Bujosa, Consolación Moltó, Thomas J. Hwang, José Carlos Tapia, Kerstin N. Vokinger, Arnoud J. Templeton, Ignasi Gich, Agustí Barnadas, Eitan Amir, and Ariadna Tibau

Background The FDA defines clinical benefit as an improvement in either the duration or the quality of life (QoL). 1 FDA criteria allow cancer drugs to be approved based on surrogate measures that will reasonably predict definitive outcomes

Full access

Counterpoint: Implementing Population Genetic Screening for Lynch Syndrome Among Newly Diagnosed Colorectal Cancer Patients—Will the Ends Justify the Means?

Michael J. Hall

with Lynch in the United States population and, more importantly, 2) to effectively improve health outcomes for patients with CRC and their relatives, because of a paucity of information on real-life access barriers, educational gaps, and patient

Full access

CGE24-096: Impact of Somatic Mutations on Outcomes of Salvage Radiation and Hormonal Therapy for Prostate Cancer Recurrence After Prostatectomy

Keisuke Otani, David J. Konieczkowski, Daniel J . Rodden, Shulin Wu, Elai Davicioni, Philip J. Saylor, Douglas M. Dahl, Chin-Lee Wu, Sophia C. Kamran, Jason A. Efstathiou, and David T. Miyamoto

) was performed to an average depth of 162X (r, 70.7–219). We tested for association between somatic mutations and clinical outcomes using the log-rank test and Cox proportional hazards model. Results: Median age at salvage was 64.5 yrs. High quality

Full access

HSR24-139: Patient-Reported Outcome Measures Used in Patients With Chronic Phase–Chronic Myeloid Leukemia: A Systematic Review of the Literature

Kathryn E. Flynn, Lovneet Saini, Aditi Kataria, Kejal Jadhav, Daisy Yang, and David Wei

for CML patients in survivorship. Patient-reported outcome (PRO) measures provide key evidence about patients’ experiences with TKIs, as TKIs differ in associated adverse events (AEs) and side effect profiles. What we understand about PROs depends on

Full access

HSR24-152: Patient-Reported Outcome (PRO) Data in Oncology NDAs Approved by the FDA (2018–2021): A Review of Criticism and Concerns in Comments From Regulators

Erin Comerford, Lindsey Norcross, Medha Sasane, Ying Zheng, and Ari Gnanasakthy

Background: Despite increasing inclusion of patient-reported outcomes (PROs) in pivotal trials, PRO data often do not make it into labeling for approved products. This is particularly true in the field of oncology, where assessment and

Full access

CLO23-042: Clinical Outcomes of Radical Radiotherapy With or Without Chemotherapy in Inoperable Locally Advanced Squamous Cell Carcinoma of Oral Cavity

Maria Philip, Jomon Raphael Chalissery, Febin Antony, Rajkrishna B, and Mathew Varghese K

to determine the benefits and overall survival in these patients treated with definitive radiotherapy with or without concurrent chemotherapy. Methods: We conducted a retrospective analysis to evaluate the clinical outcomes in patients with